We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$10.2B
AUM Growth
+$793M
Cap. Flow
+$230M
Cap. Flow %
2.25%
Top 10 Hldgs %
30.33%
Holding
229
New
13
Increased
77
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.7M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$44M
3
IQV icon
IQVIA
IQV
+$40.5M
4
MGNX icon
MacroGenics
MGNX
+$39.5M
5
SAGE
Sage Therapeutics
SAGE
+$39.1M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$222M
2
MRNA icon
Moderna
MRNA
+$47.8M
3
CI icon
Cigna
CI
+$47.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$40.5M
5
DVA icon
DaVita
DVA
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.41%
2 Industrials 0.94%
3 Technology 0.31%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUNG icon
126
Pulmonx
LUNG
$57M
$7.79M 0.08%
176,510
– –
GILD icon
127
Gilead Sciences
GILD
$165B
$7.64M 0.07%
111,000
– –
OLK
128
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$6.8M 0.07%
197,527
+45,390
+30% +$1.56M
SYNH
129
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$6.31M 0.06%
70,500
+51,500
+271% +$4.35M
SGFY
130
DELISTED
Signify Health, Inc.
SGFY
$6.09M 0.06%
200,000
– –
JNJ icon
131
Johnson & Johnson
JNJ
$599B
$5.11M 0.05%
31,000
-10,100
-25% -$1.67M
BNTX icon
132
BioNTech
BNTX
$23.3B
$5.06M 0.05%
22,600
-22,900
-50% -$4.32M
SEER icon
133
Seer Inc
SEER
$112M
$4.46M 0.04%
136,133
+25,905
+24% +$1.02M
SGEN
134
DELISTED
Seagen Inc. Common Stock
SGEN
$4.34M 0.04%
27,500
-7,800
-22% -$1.16M
SNY icon
135
Sanofi
SNY
$105B
$3.58M 0.04%
+68,000
New +$3.55M
BHVN
136
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.5M 0.03%
36,000
– –
BMRN icon
137
BioMarin Pharmaceuticals
BMRN
$11.4B
$3.38M 0.03%
40,500
+3,500
+9% +$277K
APLS
138
DELISTED
Apellis Pharmaceuticals
APLS
$3.03M 0.03%
48,000
– –
ALXN
139
DELISTED
Alexion Pharmaceuticals
ALXN
$2.63M 0.03%
14,300
-1,294,428
-99% -$222M
DRNA
140
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.28M 0.02%
61,000
-7,000
-10% -$215K
RCUS icon
141
Arcus Biosciences
RCUS
$3.54B
$2.06M 0.02%
75,000
– –
RARE icon
142
Ultragenyx Pharmaceutical
RARE
$2.81B
$2.04M 0.02%
21,400
-19,600
-48% -$2.04M
XNCR icon
143
Xencor
XNCR
$1.39B
$1.83M 0.02%
53,100
– –
ACAD icon
144
Acadia Pharmaceuticals
ACAD
$4.3B
$1.61M 0.02%
65,900
– –
ALLK
145
DELISTED
Allakos
ALLK
$1.58M 0.02%
18,500
– –
ZTS icon
146
Zoetis
ZTS
$31.9B
$1.32M 0.01%
+7,100
New +$1.23M
CLLS
147
Cellectis
CLLS
$262M
$1.29M 0.01%
83,500
– –
KURA icon
148
Kura Oncology
KURA
$948M
$1.21M 0.01%
58,000
– –
MRTX
149
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.18M 0.01%
7,300
-2,500
-26% -$401K
CCCC icon
150
C4 Therapeutics
CCCC
$396M
$1.17M 0.01%
+31,000
New +$1.11M
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bellevue Group held 229 positions worth $10.2B, up 8.4% from $9.45B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q2 2021 filing shows 13 new, 77 increased, 41 reduced and 15 closed positions. Its largest new stake was Adaptive Biotechnologies: 962,352 shares worth $39.3M. The largest sale was Alexion Pharmaceuticals, an estimated $222M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2021 buy was Adaptive Biotechnologies: 962,352 shares worth $39.3M.
  • Bellevue Group added most to Vertex Pharmaceuticals in Q2 2021, an estimated $74.7M increase.
  • Bellevue Group's biggest Q2 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $222M.
  • Bellevue Group fully exited DaVita in Q2 2021, selling an estimated $39.6M.
  • Bellevue Group's ten largest holdings make up 30% of its $10.2B portfolio in Q2 2021.
  • Bellevue Group opened 13 new positions and closed 15 in Q2 2021.
  • Bellevue Group's portfolio value rose 8.4% quarter-over-quarter to $10.2B.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.